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AbsTrACT
Introduction The Practical Approach to Care Kit (PACK) 
guide was localised for Brazil, where primary care doctors 
and nurses were trained to use it.
Methods Twenty- four municipal clinics in Florianópolis 
were randomly allocated to receive outreach training and 
the guide, and 24 were allocated to receive only the guide. 
6666 adult patients with asthma or chronic obstructive 
pulmonary disease (COPD) were enrolled, and trial 
outcomes were measured over 12 months, using electronic 
medical records. The primary outcomes were composite 
scores of treatment changes and spirometry, and new 
asthma and COPD diagnosis rates.
results Asthma scores in 2437 intervention group 
participants were higher (74.8%, 20.4% and 4.8% with 
scores of 0, 1 and 2, respectively) than in 2633 control 
group participants (80.0%, 16.8% and 3.2%) (OR for higher 
score 1.32, 95% CI 1.08 to 1.61, p=0.006). Adjusted for 
asthma scores recorded in each clinic before training 
started, the OR was 1.24 (95% CI 1.03 to 1.50, p=0.022). 
COPD scores in 1371 intervention group participants 
(77.7%, 17.9% and 4.3% with scores of 0, 1 and 2) did 
not differ from those in 1181 control group participants 
(80.5%, 15.8% and 3.7%) (OR 1.21, 95% CI 0.94 to 1.55, 
p=0.142). Rates of new asthma and COPD diagnoses, 
and hospital admission, and indicators of investigation, 
diagnosis and treatment of comorbid cardiovascular 
disease, diabetes and depression, and tobacco cessation 
did not differ between trial arms.
Conclusion PACK training increased guideline- based 
treatment and spirometry for asthma but did not affect 
COPD or comorbid conditions, or diagnosis rates.
Trial registration NCT02786030 (https:// clinicaltrials. gov/).
InTroduCTIon
Asthma and chronic obstructive pulmonary 
disease (COPD) are major contributors to 
the burden of chronic illness in Brazil. The 
Global Burden of Disease Study 2016 ranked 
COPD as the eighth highest disease in Brazil 
in terms of disability- adjusted life years lost.1 
Asthma was ranked 17th in terms of years lived 
with disability.1 Despite progress in tobacco 
control, in 2016 tobacco use was the fifth 
most important cause of disability- adjusted 
life years lost, especially through its effects on 
chronic respiratory disease.1 Epidemiological 
studies have found high rates of undiagnosed 
and untreated or inappropriately treated 
asthma and COPD in Brazil.2 3 WHO’s World 
Health Survey found that 23% of Brazilian 
adults aged 18 to 45 years reported wheezing 
summary box
What is already known?
 ► Educational outreach to primary care nurses, to 
improve diagnosis and treatment of adult chronic 
disease with clinical guidance, has been proven ef-
fective in South Africa.
What are the new findings?
 ► Similar outreach education to primary care nurses 
and doctors in Florianópolis, Brazil, increased initi-
ation and alteration of asthma treatments, and use 
of spirometry for asthma, but did not change chronic 
obstructive pulmonary disease (COPD) management 
or rates of asthma and COPD diagnosis.
What do the new findings imply?
 ► Practical Approach to Care Kit training is an effective 
method of improving management of adult asthma 
in this urban Brazilian setting.
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in the last year, of whom only 12% had a doctor diagnosis 
of asthma.3 Comorbidity is increasing,4 with high and 
growing rates of chronic conditions like cardiovascular 
disease, diabetes and depression.
Provision of good- quality primary healthcare, 
including investigation, diagnosis and appropriate treat-
ment of asthma, COPD and comorbid conditions, is a 
crucial part of the solution. Since 1998, Brazil increased 
provision of free primary care by municipalities through 
the Family Health Programme of the national Unified 
Health System.5 Brazilian municipalities that provided 
free inhaled corticosteroids (ICSs) for asthma expe-
rienced larger reductions in hospital admissions and 
deaths from asthma than those who did not,6 and those 
who provided more long- acting beta2 agonists (LABAs) 
had larger reductions in hospital admission rates for 
COPD.7 Programmes to improve asthma care in two 
cities, with physician education, and free ICS and LABA, 
also reduced hospital admissions.8 9
The present study evaluates an initiative to improve 
integrated primary care including for asthma, COPD 
and comorbid chronic conditions across a Brazilian 
city by adapting a programme that has been developed 
and delivered at scale in South Africa. The Practical 
Approach to Care Kit (PACK) programme was developed 
by the Knowledge Translation Unit (KTU) of the Univer-
sity of Cape Town Lung Institute, in collaboration with 
government health departments in South Africa.10 11 It 
has four components—a clinical decision support tool 
or guide, primary care worker training, health system 
strengthening, and monitoring and evaluation.12 13 PACK 
has been localised for, and is being used in, Nigeria,14 
Ethiopia15 and Botswana.16
PACK was localised to the Brazilian context, and specif-
ically for municipal primary healthcare clinics in the city 
of Florianópolis, between 2014 and 2016, with leadership 
by local primary care doctors mentored by the KTU.17 
Florianópolis has a population of 486 000 and was the 
first Brazilian municipality to provide universal health 
coverage under the auspices of the national Family 
Health Strategy. Although it is one of the wealthiest cities 
in Brazil, with a large private health sector, a substan-
tial proportion of its population has lower incomes and 
depends on free municipal primary care facilities. There 
are 48 municipal facilities, with ambulatory care deliv-
ered by pairs of family doctors and nurses, between one 
and seven (median 2.5) doctor–nurse pairs in each, and 
750–8500 (median 2700) adults served by each facility. 
Both nurses and doctors manage adults with respiratory 
symptoms, but nurses are not authorised to prescribe 
corticosteroids or beta2 agonists, referring patients with 
asthma or COPD to doctors for initiation or changes of 
treatments.
The purpose of using PACK in Florianópolis was to 
improve the quality and equity of primary healthcare 
for adults, while expanding and redefining the clin-
ical roles of doctors and nurses. Before the study, the 
Florianópolis city health department identified asthma, 
diabetes, hypertension, back pain and tuberculosis as 
priorities for quality improvement, noting, for example, 
that in 2016, over 60% of adults diagnosed with asthma 
had never received inhaled corticosteroids, 20% had 
also been diagnosed with COPD, 38% with hyperten-
sion or cardiovascular disease, and 12% with diabetes. 
Therefore, PACK’s emphasis on integrated diagnosis and 
management of multiple conditions was deemed appro-
priate. PACK training covered multiple conditions, but 
the current study focuses only on its effects on partici-
pants with asthma and COPD.
The objective of the trial was to evaluate the effects 
of PACK training on the diagnosis, investigation and 
treatment of asthma and COPD in adults attending 
Florianópolis municipal clinics. A parallel trial of the 
impact of the same PACK training on cardiovascular 
and diabetes care, including using PACK to expand the 
scope of nurses, was planned and is in analysis.18 This 
paper reports the impact of PACK educational outreach 
training on primary care of respiratory conditions during 
the first year after active implementation and is part of a 
Collection of papers on PACK.
MeTHods
Trial design
This was a pragmatic, parallel- group, superiority cluster 
randomised trial18 (figure 1 and figure 2). All but one of 
49 municipal clinics in Florianópolis were included in the 
trial; a small mobile clinic was excluded. Outcomes were 
measured over two baseline and one follow- up period 
(figure 1). The follow- up period was the 12 months 
after initial training ended (figure 1). The first baseline 
period, defined in the protocol,18 was the 12 months 
before follow- up began, during which initial training 
was completed (baseline 1 in figure 1). The second and 
earlier baseline period, adopted during the conduct of 
the study, was the 12 months before training began (base-
line 2 in figure 1). Baseline 1 was originally specified 
because we assumed that the intervention would have 
no effect before initial training had been completed.18 
However, trainers observed that delivery of training was 
associated with immediate effects on asthma and COPD 
care, which was likely to bias participants’ baseline char-
acteristics, and therefore also the estimates of effective-
ness during follow- up. We therefore defined the second 
baseline period before training began (baseline 2). The 
follow- up period was 1 April 2017 to 31 March 2018 
(figure 1). Baseline 1 period was 1 April 2016 to 31 March 
2017. Baseline 2 period was 1 July 2015 to 30 June 2016.
Patient and public involvement
Patients and public were not involved in carrying out this 
study. However, Brazilian health professionals and health 
professional organisations were consulted in developing 
the PACK guide.
randomisation
Clinics were grouped into six strata, defined by numbers 
of doctor–nurse teams in each clinic (1–2, 3–4 teams or 
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Figure 1 Timing of interventions, data collection and follow- up periods.
≥5 teams), and by their geographical location, which 
served as an indicator of socioeconomic position. A trial 
statistician (CL) randomly allocated clinics within each 
stratum to intervention and control arms in a 1:1 ratio 
using nQuery Advisor before the intervention began.
blinding
Outcomes were extracted from routine electronic medical 
records and so recorded without participants’ input, thus 
blinding of patients was not necessary. Blinding of health 
professionals was not possible because of the nature of 
the intervention.
study populations
Eligible participants were identified using International 
Classification of Disease (ICD-10) diagnostic codes 
in electronic medical records for each clinic visit, in a 
consolidated municipal database. Patients included were 
all those aged 18 years and over in March 2017, who 
attended a participating clinic during the first year of the 
follow- up (figure 2), with a clinical diagnosis of obstruc-
tive lung disease (ICD-10 codes 40–47) recorded in elec-
tronic medical records since 1 January 2010, when elec-
tronic medical recording began. This study population 
was subdivided into those with asthma (with or without 
COPD) and those with COPD (with or without asthma). 
An additional study population comprised all adults who 
attended participating clinics during 12 months after 
training ended, in whom the annual rates of new diag-
noses of asthma and COPD were estimated (figure 2). No 
sampling was used.
delivery of PACK in intervention and control group clinics
Both intervention and control clinics were provided 
with the PACK guide in May and June 2016, and were 
included in the health systems strengthening, and moni-
toring and evaluation components of PACK,17 but only 
intervention clinics received training during the period 
covered by this study. The trial therefore evaluates the 
effect of PACK training.
The PACK guide is an integrated, comprehensive 
clinical decision support tool for use during primary 
healthcare consultations.12 A global version of the guide 
(freely available at https:// knowledgetranslation. co. za/ 
pack/) provides an evidence- aligned and WHO guid-
ance–aligned clinical approach to common symptoms, 
including cough, difficulty breathing, wheeze and chest 
pain in its first half and the remainder covers chronic 
conditions, including asthma, COPD, tuberculosis, 
cardiovascular disease and risk, diabetes and depression, 
and health promotion. The chronic respiratory disease 
section covers investigation, diagnosis and treatment of 
asthma and COPD, use of inhalers, spacers and peak 
flow meters. The Florianópolis version, comprising 103 
pages, was provided in printed hard copy (from May 2016 
onwards) and as an interactive PDF during the late stage 
of data collection (from November 2017 onward).17 This 
version of the guide, PACK Brasil Adulto—versão Flori-
anópolis, was adapted to fit local needs and resources, 
and 49 local and national guidelines and protocols, and 
translated into Brazilian Portuguese.17 Local primary 
care professionals, medical specialists, health service 
managers and other stakeholders were involved in local-
isation. Unique features of the Florianópolis adaptation 
included the first use of a mentorship model to support 
localisation,10 guidance on smoking cessation, and expan-
sion of PACK’s colour coding system to reflect nurse and 
doctor role definitions.
PACK training comprised educational outreach for 
primary care doctors and nurses on how to use the 
PACK guide, using clinical case scenarios.12 Training 
was provided in or near the primary care facilities where 
trainees worked, entailed short interactive group sessions 
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Figure 2 CONSORT diagram of recruitment and follow- up in intervention and control clinics. COPD, chronic obstructive 
pulmonary disease.
of about 90 min which were repeated about weekly during 
initial training and fortnightly during maintenance 
training. Training sessions were led by facility trainers 
who worked in the same facility or within the local health 
system. More detail on the training model is provided 
in another paper in this Collection.13 Unique features 
of the training in Florianópolis included appointing 
interprofessional nurse–doctor pairs to deliver outreach 
sessions, embedding master trainers, responsible for 
training and supporting the facility trainers, within the 
Primary Healthcare Department, and a curriculum 
focused on locally identified priorities, including respi-
ratory conditions, diabetes, hypertension, back pain and 
tuberculosis. Initial training in intervention clinics took 
place during 12 sessions over 6 months (figure 1). After 
a pause of 3 months, 14 maintenance training sessions 
were delivered over 12 months. Training was delivered 
to 160 doctors and nurses, all of whose responsibilities 
included asthma and COPD care. Three municipal 
strikes within the context of political upheaval inter-
rupted smooth implementation.17 After initial training, 
the pairs of facility trainers visited each clinic monthly, 
and the master trainers continued to communicate with 
facility trainers using email and a WhatsApp group.
Primary outcomes
There were three primary outcomes. The first two repre-
sent key healthcare processes that in Brazil and elsewhere 
have been shown to be associated with better health 
outcomes in patients with asthma and COPD, reflect the 
quality and intensity of respiratory care, and are based 
on actions recommended in the PACK guide.6–9 19 20 The 
third primary outcome addresses the problem of under-
diagnosis.2 3
1. For participants with asthma the composite score com-
prised points awarded for (a) first prescription of an 
ICS, or ICS+LABA combination (LABA+ICS), or a 
change in prescription: stepping up from short- acting 
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beta2 agonist (SABA) to ICS or from ICS to LABA+ICS; 
or stepping down from LABA+ICS to ICS, or from ICS 
to SABA (scoring one point if at least one of these oc-
curred); and (b) request for spirometry (one point). 
The asthma score is the sum of these points, and rang-
es from 0 to 2.
2. For participants with COPD, the composite score 
comprised points awarded for (a) a first prescription 
of SABA, ICS or ICS+LABA; or a change in prescrip-
tion, stepping up from SABA to LABA or from LABA 
to ICS+LABA, or stepping down from LABA+ICS to 
LABA, or from LABA to SABA (scoring one point if 
at least one of these occurred) and (b) request for spi-
rometry (one point). The COPD score is the sum of 
these points, and ranges from 0 to 2.
3. At clinic level, the diagnosis rate was defined as the 
ratio between numbers of new diagnoses of asthma or 
COPD in patients aged 18 years and over to the total 
numbers of patients aged 18 years and over attending 
each clinic during baseline and 12- month follow- up 
periods.
secondary outcomes
Secondary outcomes were the disaggregated treatment 
and spirometry components of asthma and COPD 
scores, prescriptions to support tobacco cessation (nico-
tine replacement therapy, nortriptyline or bupropion), 
cardiovascular disease (ICD-10 I00–I99) diagnosed for 
the first time, diabetes mellitus (ICD-10 E10–E14) diag-
nosed for the first time, cardiovascular risk assessed (ie, 
blood pressure recorded, or cholesterol, glucose or ECG 
tests requested), depression (ICD-10 F32–F34) diag-
nosed for the first time and medication for depression 
(tricyclic and related antidepressants, selective serotonin 
re- uptake inhibitors or monoamine oxidase inhibitors) 
prescribed for the first time. Outcomes relating to cardi-
ovascular disease, diabetes and depression were indica-
tors of awareness and management of potential comor-
bidity in people with chronic respiratory disease. Clinical 
level ratios between numbers of hospital admissions for 
asthma or COPD, and total numbers of patients aged 
>18 attending each clinic during baseline and follow- up 
periods, were respiratory health indicators.
Data collection and management
Quantitative data on outcomes and baseline variables 
were extracted from the municipal health department’s 
electronic medical records. Clinical data (including 
coded symptoms, ICD-10 coded diagnoses, prescrip-
tions and test requests) were routinely entered during 
each consultation by a doctor or nurse, and linked at 
city, clinic and patient levels. The database was actively 
managed and regularly interrogated by a member of the 
Primary Healthcare Department (MPdA).
Sample size and power
The sample size calculation for patients with asthma 
assumed, based on previous medical records, that about 
2900 eligible patients with asthma would attend 48 partic-
ipating clinics during the year of follow- up, with mean 
asthma scores of 0.43 (SD 0.50) in the control group and 
intra- clinic correlation (ICC) of 0.033. The sample size 
calculation for patients with COPD assumed that about 
1400 eligible patients with COPD would attend partic-
ipating clinics during the year of follow- up, with mean 
COPD scores 0.42 (SD 0.48) in control clinics and ICC 
of 0.055. This would provide 90% power to detect a 26% 
increase in mean asthma score (0.54 vs 0.43), and a 33% 
increase in mean COPD score (0.56 vs 0.42), with 5% 
significance. At clinic level, the mean annual rate of new 
diagnoses of asthma or COPD was 11 (SD 4.6) per 1000 
patients aged >18 attending for any reason, providing 
85% power to detect a 36% increase in rates of diagnosis 
(15 vs 11 per 1000 per year). With Bonferroni correc-
tion to the significance level to account for having three 
primary outcomes (p=0.05/3=0.017), the power to detect 
these differences as significant at the 1.7% level was 84%, 
82% and 73%, respectively.
statistical analysis
Statistical analyses were conducted to estimate the magni-
tude of effects by comparing outcomes between inter-
vention and control groups, using Stata V.15 statistical 
software. Diagnosis rates in each clinic were compared 
at clinic level using linear regression. All other outcomes 
were compared at individual patient level, using regres-
sion models with robust adjustment for intra- cluster 
correlation of the outcome by clinic. Ordinal logistic 
regression was used for analyses with asthma and COPD 
scores as outcomes. Logistic regression was used for all 
other, binary, outcomes. Three sets of all analyses were 
carried out, first without adjustment for baseline values 
of the respective outcome, second with adjustment for 
baseline values recorded during baseline 1 and third with 
adjustment for baseline values recorded during baseline 
2 (figure 1). The baseline values used for adjustment were 
mean values recorded in each clinic, instead of individual 
level values, so as to be able to include participants newly 
diagnosed during the follow- up period. All regression 
models included randomisation stratum as a covariate. 
Intra- cluster correlation coefficient for each outcome 
variable was estimated using one- way analysis of variance. 
We carried out subgroup analyses, to test whether effects 
differed between participants with newly or previously 
diagnosed asthma or COPD, by adding arm–subgroup 
interaction terms to the regression models. We also 
tested whether effects differed between subgroups of 
participants with both asthma and COPD and those with 
only asthma or COPD.
ethics and research governance
Ethical guidance on cluster randomised trials and on 
use of medical records for research was adhered to.21 22 
Identification of eligible participants and outcome meas-
urement used electronic medical records without study- 
specific patient contact. It was not feasible to obtain 
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patients’ consent to be randomised to intervention or 
control arms because randomisation and delivery of the 
intervention were at clinic level.
Patients were not asked for consent for their electronic 
medical records to be used for this research because 
it was not feasible. However, we adhered to the ethical 
principles for use of medical records without patients’ 
consent,22 as follows. The research had a clear public 
benefit. We obtained approval for the study from the lead 
doctors and nurses managing the programme. Use of the 
data for research did not influence decisions about indi-
viduals’ care. Only health department data managers had 
access to personal identifiers. Data with patient identifiers 
were held by the Florianópolis City Health Department 
as part of routine data management, and anonymised 
unlinked data were securely stored and analysed at the 
University of East Anglia.
resulTs
The trial participants comprised 6666 adults with a new 
or previous diagnosis of asthma or COPD who attended a 
participating clinic for any reason during 12 months after 
the end of initial training (figure 2). The median number 
of visits per participant during this period was 5 (IQR 
2–9). The median number of participants in each control 
clinic was 115 (range, 34–504) and the median number 
in each intervention clinic was 133 (range, 43–364). Of 
the 6666 participants, 3355 (2633 with asthma and 1181 
with COPD, including 459 with both) attended control 
clinics and 3311 (2437 with asthma and 1371 with COPD, 
including 497 with both) attended intervention clinics 
(figure 2, table 1). Two- thirds (67%) of participants were 
women, and the mean age at start of follow- up was 51.4 
(SD 18.3) years. Participants with asthma were less likely 
than those with COPD to be men (29% vs 44%) and 
tended to be younger (mean ages 47.8 and 62.6 years, 
respectively) (table 1). These participants were identified 
among all 72 324 adults who attended control clinics and 
81 750 who attended intervention clinics during the same 
period. All participants were included in the assessment 
of trial outcomes, either at individual level (for partici-
pants with asthma or COPD) or at clinic level (for assess-
ment of rates of new asthma and COPD diagnoses among 
all attendees).
The baseline characteristics of participants with asthma 
or COPD, or both, in intervention and control clinics were 
compared if they attended a participating clinic during 
either baseline 1 or baseline 2 periods (table 1, figure 2). 
Participants newly diagnosed during the follow- up period 
are excluded from these results because these data were 
mostly not available or applicable to them. During both 
baseline periods, participants with asthma and those with 
COPD in intervention clinics were slightly less likely to 
be men and had slightly higher mean ages than those in 
control clinics. They were also slightly more likely to have 
ever received prescriptions for ICS, SABA and LABA+ICS. 
Participants with asthma in intervention clinics were 
slightly more likely than those in control clinics to have 
treatment started or changed or spirometry requested 
during the baseline periods, resulting in higher asthma 
scores; these differences were greater during baseline 1 
than during baseline 2. Participants with COPD had the 
same pattern of differences between intervention and 
control clinics in treatments and spirometry at baseline, 
resulting in higher COPD scores in intervention clinics. 
Differences in COPD scores were larger during baseline 1 
than during baseline 2. Management of comorbid cardio-
vascular disease, diabetes and depression was similar in 
intervention and control clinics. Rates of new diagnoses 
of asthma and COPD were similar in intervention and 
control clinics during baseline 1 but were slightly lower 
in intervention clinics during baseline 2. Hospital admis-
sion rates were similar in intervention and control clinics.
Trial outcomes during the 12 months of follow- up are 
shown in table 2. Among participants with asthma, those 
in intervention clinics were more likely to have a start 
or change in treatment (19.0% vs 15.1%, p=0.012) and 
to have spirometry requested (11.0% vs 8.1%, p=0.012), 
resulting in higher asthma score (p=0.006). Among 
participants with COPD, those in intervention clinics 
were not more likely to have a start or change in treat-
ment (10.7% vs 10.1%, p=0.699) or to have spirometry 
requested (16.1% vs 13.0%, p=0.053), resulting in no 
difference in COPD score (p=0.142). Among participants 
with asthma or COPD, or both, there were no differences 
in management of comorbidities or tobacco cessation 
medication, which, with the exception of cardiovascular 
risk assessment, were all less than 4%. Rates of new diag-
noses of asthma and COPD, and of hospital admissions, 
did not differ between intervention and control clinics.
The magnitude of effects of the intervention on trial 
outcomes were estimated with and without adjustment 
for clinic level mean baseline values of the corresponding 
outcome variable (table 3). The OR of having a higher 
asthma score was 1.32 (95% confidence limit (CL) 
1.08 to 1.61, p=0.006) in intervention clinics compared 
with control clinics, without adjustment for baseline. 
The corresponding adjusted OR was 1.15 (0.94 to 1.41, 
p=0.173) with adjustment for baseline values recorded 
in each clinic during baseline 1, and 1.24 (95% CL 1.03 
to 1.50, p=0.022) with adjustment for baseline values 
recorded in each clinic during baseline 2. ORs for the 
two components of the asthma score (treatment and 
spirometry) were similar to those for the composite 
asthma score, except that the OR for start or change 
of treatment remained statistically significant at the 5% 
level with adjustment for baseline values recorded during 
baseline 1 (OR 1.21, 95% CL 1.01 to 1.45, p=0.041). In 
participants with COPD, ORs were slightly higher than 
one for all but one of the outcomes, but none of these 
was statistically significant at the 5% level. Management 
of comorbid cardiovascular disease, diabetes and depres-
sion, prescriptions for tobacco cessation, and rates of new 
asthma and COPD diagnosis, and of hospital admissions, 
did not differ between intervention and control clinics, 
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Table 1 Baseline characteristics of participants* in intervention and control arms
Baseline 1
(before follow- up began)
Baseline 2
(before training began)
Control Intervention Control Intervention
N % N % N % N %
Participants with asthma 2206 100.0 2017 100.0 2161 100.0 1918 100.0
Sex (male) 614 27.8 515 25.5 591 27.4 485 25.3
Inhaled corticosteroid ever 820 37.2 814 40.4 752 34.8 703 36.7
Short acting beta2- agonist ever 761 34.5 755 37.4 705 32.6 652 34.0
Long acting beta2- agonist+ICS ever 302 13.7 320 15.9 269 12.5 275 14.3
Any of the above ever prescribed 995 45.1 1005 49.8 911 42.2 883 46.0
†Asthma score=0 1782 80.8 1502 74.5 1748 80.9 1483 77.3
Asthma score=1 366 16.6 428 21.2 348 16.1 369 19.2
Asthma score=2 58 2.6 87 4.3 65 3.0 66 3.4
Asthma score: start or change treatment‡ 339 15.4 387 19.2 319 14.8 333 17.4
Asthma score: spirometry‡ 143 6.5 215 10.7 159 7.4 168 8.8
COPD ever diagnosed 442 20.0 468 20.2 437 20.2 453 23.6
Mean SD Mean SD Mean SD Mean SD
Clinic level asthma score 0.214 0.107 0.293 0.124 0.206 0.110 0.287 0.119
Age (years) 48.3 18.0 49.1 17.9 48.0 18.8 48.7 17.8
N % N % N % N %
Participants with COPD 1042 100.0 1190 100.0 1025 100.0 1169 100.0
Sex (male) 450 43.2 493 40.7 445 43.4 471 40.3
Inhaled corticosteroid ever 343 32.9 390 32.2 306 29.9 342 29.5
Short acting beta2- agonist ever 302 29.0 341 32.2 274 26.7 299 25.6
Long acting beta2- agonist+ICS ever 213 20.9 264 28.1 188 18.3 223 19.1
Any of the above ever prescribed 463 44.4 549 45.3 417 40.7 482 41.2
COPD score=0† 88.1 84.6 943 77.8 849 82.8 948 81.1
COPD score=1 130 12.5 220 18.2 145 14.2 175 15.0
COPD score=2 31 3.0 48 4.0 31 3.0 46 4.9
COPD score: start or change treatment‡ 93 8.9 137 11.3 95 9.3 125 10.7
COPD score: spirometry‡ 99 9.5 181 14.9 112 10.9 142 12.2
Asthma ever diagnosed 442 42.4 468 38.6 437 42.6 453 38.8
Mean SD Mean SD Mean SD Mean SD
Age (mean) 62.2 13.4 61.9 13.4 61.7 13.1 61.1 13.6
N % N % N % N %
Participants with asthma or COPD 2806 100.0 2761 100.0 2749 100.0 2632 100.0
Sex (male) 885 31.5 840 30.4 857 31.2 794 30.1
Cardiovascular disease newly diagnosed§ 91 3.2 124 4.5 1147 4.2 130 4.9
Cardiovascular risk assessed¶ 1785 63.6 1751 63.4 1829 66.5 1791 68.0
Diabetes newly diagnosed 91 3.2 113 4.1 86 3.1 97 3.7
Nicotine or buproprion or nortriptyline prescribed 76 2.7 102 3.7 87 3.2 90 3.4
Depression newly diagnosed 69 2.5 107 3.9 65 2.4 80 3.0
Antidepressant treatment started 87 3.1 118 4.3 105 3.8 117 4.4
Mean SD Mean SD Mean SD Mean SD
Clinic level COPD score 0.186 0.078 0.269 0.173 0.202 0.834 0.225 0.102
Age (years) 51.3 18.0 52.7 17.8 51.1 17.8 52.2 17.6
Continued
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Baseline 1
(before follow- up began)
Baseline 2
(before training began)
Clinic level diagnosis and hospital admission ratios**
New asthma and COPD diagnoses 10.3 4.2 10.9 4.7 11.2 4.3 9.5 3.1
New asthma diagnoses 7.3 3.2 7.4 3.9 7.8 3.7 6.2 2.7
New COPD diagnoses 3.0 1.9 3.6 2.2 3.4 1.4 3.3 1.4
Hospital admissions for asthma or COPD 1.3 1.1 0.80 0.61 0.57 0.65 0.59 0.46
*Excludes participants newly diagnosed with asthma or COPD during follow- up.
†Primary outcomes.
‡Components added to create primary outcomes.
§ICD-10 I00–I99.
¶Blood pressure, cholesterol,glucose and/or ECG recorded.
**No of new diagnoses or hospital admissions: 1000 adults visiting clinic during the year.
COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid.
Table 1 Continued
with or without adjustment for baselines. Effect estimates 
did not differ between subgroups with newly or previously 
diagnosed asthma or COPD, or between subgroups with 
both asthma and COPD and those with only one condi-
tion (p>0.05 for interaction terms) (results not shown).
dIsCussIon
The trial indicates that educational outreach training of 
primary care doctors and nurses to use the PACK guide 
for the management of respiratory diseases, compared 
with provision of the guide without training, was asso-
ciated with small increases in initiation or change of 
treatment and use of spirometry for adults diagnosed 
with asthma. Conservatively using a 1.7% significance 
level, to account for having three primary outcomes, the 
difference in asthma score remains statistically signif-
icant (p=0.006). Similar patterns of outcomes and ORs 
were seen for participants with COPD, but these asso-
ciations were not statistically significant. The interven-
tion was not shown to affect the rate of new diagnoses 
of asthma or COPD, prescriptions for tobacco cessation, 
or the management of comorbid cardiovascular disease, 
diabetes or depression, all of which were very low with 
the exception of cardiovascular risk assessment which 
included blood pressure measurement.
When estimated effects on the primary endpoints were 
adjusted to account for clinical activity during baseline 
1 (which included training for at least 8 months), the 
magnitude of these effects was reduced, and estimated 
effects on primary outcomes became non- significant. The 
latter adjustment, proposed in the original protocol,18 
might however be excessive if, as the results suggest, 
training had begun to have effects during baseline one 
period (table 1). However, the OR for start or change of 
treatment in participants with asthma—the main compo-
nent of the asthma score—was consistent despite either 
adjustment and remained statistically significant.
Interpretation of these results requires several consid-
erations. The trial evaluated only the training component 
of the programme, and not the other components (PACK 
guide, health system strengthening and monitoring 
and evaluation), which were provided to both control 
and intervention clinics. However, access to the guide 
may indeed have influenced clinical practice in control 
clinics, as suggested by the 60% increase (0.330/0.206) in 
mean asthma scores and the 39% increase (0.281/0.202) 
in mean COPD scores, in control clinics from baseline 2 
(table 1) to the follow- up period (table 2). These changes 
in control clinics reduced the trial’s scope for demon-
strating additional improvements in intervention clinics 
due to training alone.
We have used this approach to evaluating the impact of 
PACK training in our previous trials with other versions 
of PACK, with small, consistent and generally positive 
results.23–26 The current trial demonstrates small but 
significant effects on improving management of at least 
one endpoint. As we have previously argued, pragmatic 
trials, with their potential for contamination despite 
cluster randomisation, unplanned co- interventions and 
other factors, when negative are of little help to health 
planners (other than in ruling out harm) but, when posi-
tive, provide compelling evidence for adopting a complex 
intervention, especially if the new method is well received 
by providers and recipients of care.27
The selection of participants and data collection 
methods need to be considered. Compared with our 
prior calculations, the actual sample sizes and statis-
tical power were greater, but the differences in primary 
outcomes were smaller than anticipated. In contrast to 
our previous trials in low- income and middle- income 
countries, the relatively high rates of previous treatment 
among participants before training began (table 1) may 
have limited the scope for training to further increase 
initiation and changes of treatment. Almost half of 
participants with asthma and over 40% with COPD 
had already received some treatment, and over 40% 
of both groups had already received ICS, either alone 
or in combination with a LABA. These treatment rates 
are similar to those reported in surveys from Brazil as 
a whole but are still not optimal.28 29 In asthma, use of 
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Table 2 Follow- up values of outcome variables in intervention and control clinics
Control Intervention P value ICC
Individual level outcomes N % N %
Participants with asthma 2633 100.0 2437 100.0
*Asthma score=0 2107 80.0 1823 74.8 0.006† 0.028
Asthma score=1 442 16.8 497 20.4
Asthma score=2 84 3.2 117 4.8
Asthma score component: spirometry 212 8.1 267 11.0 0.012 0.017
Asthma score component: start or change of 
treatment, including:
398 15.1 464 19.0 0.012 0.020
ICS started 156 5.9 178 7.3 0.067 0.039
Long- acting beta2- agonist+ICS started 63 2.4 85 3.5 0.083 0.067
Treatment stepped up 30 1.1 43 1.8 0.096 0.074
Treatment stepped down 22 0.8 20 0.8 0.932 0.023
Participants with COPD 1181 100.0 1371 100.0
*COPD score=0 951 80.5 1065 77.7 0.142 0.036
COPD score=1 186 15.8 245 17.9
COPD score=2 44 3.7 61 4.5
COPD score: spirometry 154 13.0 220 16.1 0.053 0.034
COPD score: start or change treatment, including: 120 10.2 147 10.7 0.699 0.013
ICS started 61 5.2 65 4.7 0.513 0.006
Short- acting beta2- agonist 51 4.3 62 4.5 0.880 0.005
Long- acting beta2- agonist+ICS started 63 5.3 83 6.1 0.456 0.018
Participants with asthma or COPD 3355 100.0 3311 100.0
Cardiovascular disease newly diagnosed 107 3.2 119 3.6 0.705 0.005
Cardiovascular risk assessed 2170 64.7 2141 64.7 0.698 0.034
Diabetes newly diagnosed 66 2.0 96 2.9 0.057 0.009
Nicotine or buproprion or nortriptyline prescribed 102 3.0 115 3.5 0.419 0.005
Depression newly diagnosed 81 2.4 104 3.1 0.266 0.020
Antidepressant treatment started 121 3.6 132 4.0 0.607 0.013
  Mean SD Mean SD P‡
Clinic level asthma score 0.330 0.142 0.361 0.131 0.456‡ Not applicable
Clinic level COPD score 0.281 0.175 0.293 0.150 0.808‡ Not applicable
Clinic level diagnosis and hospital admission ratios§     
#New asthma and COPD diagnoses 9.3 3.0 9.4 4.0 0.884‡ Not applicable
New asthma diagnoses 6.2 1.8 6.0 2.6 0.706‡ Not applicable
New COPD diagnoses 3.1 1.9 3.3 2.1 0.851‡ Not applicable
Hospital admissions for asthma or COPD 1.1 1.2 1.1 0.0 0.822‡ Not applicable
*Primary outcomes.
†Ordinal logistic regression model. Logistic regression models for all other individual- level outcomes. All individual- level regression models 
adjusted for randomisation strata and intra- cluster correlation of outcomes.
‡Linear regression models adjusted for randomisation strata.
§No of new diagnoses or hospital admissions: 1000 adults visiting clinic during the year.
COPD, chronic obstructive pulmonary disease; ICC, intra- cluster correlation coefficient; ICS, inhaled corticosteroid.
ICS and other controllers should be higher and so the 
increase in prescribing in the present study, although 
small, is gratifying. But for COPD, as Zimmermann Teix-
eira and colleagues report, the more common problem 
in Brazil is overtreatment with ICS for mildly severe 
COPD and undertreatment for severe disease.29 Thus, 
the relatively high use of ICS in primary care patients 
observed in Florianópolis, who might have milder 
disease compared with others receiving specialist care, 
may still provide room for improvement.
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Our use of routine electronic medical records to iden-
tify and characterise eligible participants may have led to 
inclusion of some participants to whom trial outcomes 
were not relevant. Some may have been diagnosed with 
asthma or COPD years earlier but asymptomatic or well 
controlled during the trial, and thus did not need the 
investigations or treatments used as trial outcomes. We 
included participants newly diagnosed with asthma or 
COPD during the follow- up period because they would 
presumably be most in need of investigation or new treat-
ments. Electronic medical records did not permit us to 
accurately assess participants’ respiratory health status, 
as respiratory symptom questionnaires and spirom-
etry would have done, to identify individuals who most 
needed to start or change treatment or to evaluate health 
outcomes. Instead, we relied on process indicators of 
effective and improved management.
Other trial design issues relate to the nature and 
intensity of training. PACK training is performed on- site 
and in- service, and is continuous, being conducted in 
short sessions at fortnightly intervals. Since the guide is 
comprehensive and covers the the most common condi-
tions managed in primary care facilities, it is possible that, 
within the trial’s training period, there was insufficient 
emphasis on the management of respiratory conditions 
to produce larger effects. The follow- up period might 
also be too short to detect changes in clinical practice. 
We will therefore continue to monitor outcomes after 
completion of this trial, for delayed effects, or changes in 
control clinics after they receive training.
This study setting had favourable features. Florianópolis 
is a leader in Brazil both in its primary care provision and 
in its electronic medical record system which provides 
considerable scope for evaluating practice innovations 
such as PACK. Electronic medical records enabled us to 
characterise clinical practices and identify and include all 
eligible patients who used municipal clinics in the entire 
city, thus enhancing generalisability and providing a large 
sample size at minimal cost. This follows our successful 
use of electronic medical records in randomised trials of 
PACK’s precursors in South Africa.24 25
This study contributes to implementation research on 
methods for improving primary respiratory care. The 
results support the growing evidence of the effective-
ness of the training component of the PACK approach 
in which clinicians are introduced to customised, up- to- 
date, evidence- based, point- of- care clinical decision 
support.23–26 Thus, although the impact of training is not 
large nor consistent across asthma and COPD, within 
the context of the global implementation of PACK as 
a learning health system, the results add evidence that 
the training intervention is effective on a different conti-
nent and in a different socioeconomic and health system 
context. This trial does not explain how PACK works, 
or what element is most effective, but supports qualita-
tive and quantitative evidence previously reported in 
more than 50 peer- reviewed publications.23 24 30 A qual-
itative process evaluation is under way. Early findings 
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indicate that trainers, trainees and health officials were 
enthusiastic about PACK and that training stimulated a 
desire for continuing professional development. Atten-
dance at training sessions was high, but staff turnover 
meant that supplementary training was needed for new 
staff. Training was felt to improve cooperation between 
doctors and nurses, while expanding nurses roles’ and 
confidence. Political changes in local government, and 
fiscal constraints arising from Brazil’s economic crisis, 
did not affect implementation during the study. The 
results of this trial are consistent with the most recent and 
comprehensive review of healthcare provider strategies 
to improve performance which advocates for combining 
training with group problem solving and supervision, 
both of which are built into the PACK implementation 
approach.31
The results support expanding nurses’ roles and 
strengthening nurse–doctor co- operation in asthma 
care. Nurses were not authorised to prescribed asthma 
or COPD medication or to request spirometry, but they 
were trained to refer patients whom they identified as 
needing these interventions to doctors in their primary 
care teams. Training doctors and nurses together aimed 
to align their clinical decision- making. These results add 
to previous evidence about interventions to promote 
interprofessional collaboration.32 33
In conclusion, this study shows that it was feasible to 
localise and implement PACK in municipal primary care 
services across a Brazilian city, and that PACK training 
led to improvements in asthma care within a year of 
completing initial training.
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